251 related articles for article (PubMed ID: 21737767)
41. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
[TBL] [Abstract][Full Text] [Related]
42. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
43. Restless legs syndrome and near-infrared light: An alternative treatment option.
Mitchell UH; Myrer JW; Johnson AW; Hilton SC
Physiother Theory Pract; 2011 Jul; 27(5):345-51. PubMed ID: 20977377
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of dopamine agonists in restless legs syndrome.
Hornyak M; Trenkwalder C; Kohnen R; Scholz H
Sleep Med; 2012 Mar; 13(3):228-36. PubMed ID: 22281001
[TBL] [Abstract][Full Text] [Related]
45. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep).
Allen RP; Kosinski M; Hill-Zabala CE; Calloway MO
Sleep Med; 2009 May; 10(5):531-9. PubMed ID: 18805054
[TBL] [Abstract][Full Text] [Related]
46. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial.
Simon JA; Duncan C; Huggins J; Solkowitz S; Carmody TP
Nicotine Tob Res; 2009 Jun; 11(6):663-9. PubMed ID: 19395688
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial.
Ma JF; Wan Q; Hu XY; Sun SG; Wang WZ; Zhao ZX; Wang YJ; Liu CF; Li JM; Jiang YP; Chen SD
Sleep Med; 2012 Jan; 13(1):58-63. PubMed ID: 22137119
[TBL] [Abstract][Full Text] [Related]
48. [Restless legs syndrome in patients on dialysis for kidney insufficiency: effect of medication].
Hohl-Radke F; Aedtner F; Domröse U; Neumann KH; Staedt J
Dtsch Med Wochenschr; 2008 Jan; 133(3):71-5. PubMed ID: 18186007
[TBL] [Abstract][Full Text] [Related]
49. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome.
Winkelman JW; Bogan RK; Schmidt MH; Hudson JD; DeRossett SE; Hill-Zabala CE
Mov Disord; 2011 Sep; 26(11):2065-72. PubMed ID: 21611981
[TBL] [Abstract][Full Text] [Related]
50. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
Saletu M; Anderer P; Högl B; Saletu-Zyhlarz G; Kunz A; Poewe W; Saletu B
J Neural Transm (Vienna); 2003 Jun; 110(6):611-26. PubMed ID: 12768357
[TBL] [Abstract][Full Text] [Related]
51. Investigating the response to intravenous iron in restless legs syndrome: an observational study.
Hornyak M; Scholz H; Kiemen A; Kassubek J
Sleep Med; 2012 Jun; 13(6):732-5. PubMed ID: 22503006
[TBL] [Abstract][Full Text] [Related]
52. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.
Benes H; Mattern W; Peglau I; Dreykluft T; Bergmann L; Hansen C; Kohnen R; Banik N; Schoen SW; Hornyak M
J Neurol; 2011 Jun; 258(6):1046-54. PubMed ID: 21188406
[TBL] [Abstract][Full Text] [Related]
53. Frequency, severity and risk factors for restless legs syndrome in healthcare personnel.
Civi S; Kutlu R; Tokgoz S
Neurosciences (Riyadh); 2012 Jul; 17(3):230-5. PubMed ID: 22772928
[TBL] [Abstract][Full Text] [Related]
54. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.
Lal R; Ellenbogen A; Chen D; Zomorodi K; Atluri H; Luo W; Tovera J; Hurt J; Bonzo D; Lassauzet ML; Vu A; Cundy KC
Clin Neuropharmacol; 2012; 35(4):165-73. PubMed ID: 22664749
[TBL] [Abstract][Full Text] [Related]
55. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
Wilens TE; Spencer TJ; Biederman J; Girard K; Doyle R; Prince J; Polisner D; Solhkhah R; Comeau S; Monuteaux MC; Parekh A
Am J Psychiatry; 2001 Feb; 158(2):282-8. PubMed ID: 11156812
[TBL] [Abstract][Full Text] [Related]
56. Targeted Pressure on Abductor Hallucis and Flexor Hallucis Brevis Muscles to Manage Moderate to Severe Primary Restless Legs Syndrome.
Kuhn PJ; Olson DJ; Sullivan JP
J Am Osteopath Assoc; 2016 Jul; 116(7):440-50. PubMed ID: 27367949
[TBL] [Abstract][Full Text] [Related]
57. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.
García-Borreguero D; Högl B; Ferini-Strambi L; Winkelman J; Hill-Zabala C; Asgharian A; Allen R
Mov Disord; 2012 Feb; 27(2):277-83. PubMed ID: 22328464
[TBL] [Abstract][Full Text] [Related]
58. Lower molecular weight intravenous iron dextran for restless legs syndrome.
Cho YW; Allen RP; Earley CJ
Sleep Med; 2013 Mar; 14(3):274-7. PubMed ID: 23333678
[TBL] [Abstract][Full Text] [Related]
59. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients.
Thorp ML; Morris CD; Bagby SP
Am J Kidney Dis; 2001 Jul; 38(1):104-8. PubMed ID: 11431189
[TBL] [Abstract][Full Text] [Related]
60. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
